Search

Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
When time is muscle: One dad shares his story to advocate for Duchenne newborn screening
Sarepta Therapeutics anuncia la convocatoria de solicitudes para el Programa de concesión de subvenciones para LGMD 2024
Sarepta Therapeutics Announces Call for Applications for the 2024 LGMD Grant Award Program
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
Sarepta Therapeutics anuncia convocatoria de solicitudes para el 7.º Route 79 anual, el Programa de Becas de Duchenne